STK11 and lung cancer: We also recognize that the scoring models for ranking cancer treatments will evolve with new discoveries of biomarkers and treatments, especially those involving combinations of immuno-oncology, targeted and chemotherapeutic agents and the need to address emerging evidence for markers of possible resistance that are context-dependent (eg, STK11 mutations for PD-1 inhibitors in KRAS mutant lung cancers.37